[ad_1]
Ottawa, Ontario, May 28, 2021 / CNW /- Tetra Pak Biopharmaceuticals (“Tetra Pak“Or”the company“) (Toronto Stock Exchange:To be determined) (Over-the-counter market:TBPMF) (FRA: JAM1), a leader in the discovery and development of cannabinoid-derived drugs, is pleased to announce that all matters have been submitted to the company’s annual general meeting and special meeting (“meeting”) The company’s general meeting of shareholders held via an online audio webcast earlier today was approved.
Director elections and resolutions
All nominees listed in Tetra’s Management Information Notice are dated April 20, 2021, As the supplementary date of the supplementary management information notice May 18, 2021 (This”round“), that is, PhD. Guy Chamberland, Dale Will, Brent Norton, John King with Katherine Alder, To be elected as a director of the company until the next annual shareholder meeting or his successor is elected or appointed.The initial management information announcement date is April 20, 2021 Mr. is being listed. Guy Chamberland, Dell Norton with Calmerton And madam. Dale Will As a director candidate for the next year.After that date, management continued to work hard to identify suitable director candidates to increase its board members, thus nominating John King with Katherine Alder Serve as company director.In addition, in May 18, 2021, Mr. Calmerton Announced that it will not seek re-election as a director at this shareholders meeting.
As set out in the circular, the proposal to appoint McGovern Hurley LLP as the company’s auditor and authorize the company’s board of directors to determine the remuneration payable to the auditor has been approved by a majority of shareholders at the general meeting.
The company’s shareholders’ ordinary resolution agrees to the revised and restated company’s comprehensive equity incentive compensation plan (“Revised and restated comprehensive plan”) (modify and restate the effectiveness of the company’s current 2020 comprehensive equity incentive plan) and approve the unallocated rewards under it. The entire term is three (3) years, as described in the circular by the majority of shareholders at the meeting The revised and restated comprehensive plan stipulates the revised terms of the amendment and reflects other amendments of a “housekeeping” nature, so that the company’s equity incentive compensation plan conforms to the Toronto Stock Exchange corporate manual. In addition, the revised and restated comprehensive plan Provides a simplified ownership and settlement mechanism for stock units.
Please refer to the voting result report submitted by the company based on the company’s SEDAR file at www.sedar.com on May 28, 2021 Further details on the above matters.
About Tetra Bio-Pharma Inc.:
Tetra Pak Biopharmaceuticals (Toronto Stock Exchange:To be determined) (Over-the-counter market:TBPMF) (FRA:JAM1) is a leader in the discovery and development of cannabinoid-derived drugs, with clinical projects approved by the FDA and Health Canada, aiming to bring new prescription drugs and treatments to patients and their healthcare providers. Its evidence-based scientific approach allows us to develop a series of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at its core, Tetra Bio-Pharma focuses on providing the strict scientific verification and safety data required by regulatory agencies, doctors and insurance companies to integrate into the existing biopharmaceutical industry.
For more information, please visit: www.tetrabiopharma.com
Source: Tetra Bio-Pharma Inc.
View original content: http://www.newswire.ca/en/releases/archive/May2021/28/c7902.html
[ad_2]
Source link
